Abstract:Alport syndrome (AS) is a hereditary kidney disease associated with proteinuria, hematuria and progressive kidney failure. It is characterized by a defective glomerular basement membrane caused by mutations in type IV collagen genes COL4A3/A4/A5 which result in defective type IV collagen α3, α4, or α5 chains, respectively. Alport syndrome has three different patterns of inheritance: X-linked, autosomal and digenic. In a study of CKD of unknown etiology type IV collagen gene mutations accounted for the majority of the cases of hereditary glomerulopathies which suggests that AS is often underrecognized. The natural history and prognosis in patients with AS is variable and is determined by genetics and environmental factors. At present, no preventive or curative therapies exist for AS. Current treatment includes the use of renin-angiotensin-aldosterone system inhibitors which slow progression of kidney disease and prolong life expectancy. Ramipril was found in retrospective studies to delay the onset of ESKD and was recently demonstrated to be safe and effective in children and adolescents, supporting that early initiation of Renin Angiotensin Aldosterone System (RAAS) blockade is very important. Mineralocorticoid receptor blockers might be favorable for patients who develop "aldosterone breakthrough." While the DAPA-CKD trial suggests a beneficial effect of SGLT2 inhibitors in CKD of non-metabolic origin, only a handful of patients had Alport in this cohort, and therefore conclusions can't be extrapolated for the treatment of AS with SGLT2 inhibitors. Advances in our understanding on the pathogenesis of Alport syndrome has culminated in the development of innovative therapeutic approaches that are currently under investigation. We will provide a brief overview of novel therapeutic targets to prevent progression of kidney disease in AS. Our review will include bardoxolone methyl, an oral NRf2 activator; lademirsen, an anti-miRNA-21 molecule; sparsentan, dual endothelin type A receptor (ETAR) and angiotensin 1 receptor inhibitor; atrasentan, oral selective ETAR inhibitor; lipid-modifying agents, including cholesterol efflux transporter ATP-binding cassette A1 (ABCA1) inducers, discoidin domain receptor 1 (DDR1) inhibitors and osteopontin blocking agents; the antimalarial drug hydroxychloroquine; the antiglycemic drug metformin and the active vitamin D analog paricalcitol. Future genomic therapeutic strategies such as chaperone therapy, genome editing and stem cell therapy will also be discussed.

Laminin α2-mediated focal adhesion kinase activation triggers Alport glomerular pathogenesis

Glomerular Elasticity and Gene Expression Patterns Define Two Phases of Alport Nephropathy

Pharmacological approach and diagnosis for Alport syndrome

The β isoform of GSK3 mediates podocyte autonomous injury in proteinuric glomerulopathy.

PDGF-D Is Dispensable for the Development and Progression of Murine Alport Syndrome

Accelerated Podocyte Detachment and Progressive Podocyte Loss from Glomeruli with Age in Alport Syndrome.

A Novel Deep Learning Approach for Analyzing Glomerular Basement Membrane Lesions in a Mouse Model of X-Linked Alport Syndrome

Correlation between ultrastructural changes of glomerular basement membrane and abnormal distribution of laminins in patients with Alport's syndrome]

Inhibition of Matrix Metalloproteinases During Chronic Allograft Nephropathy in Rats

Dysregulated Expression of Microrna-21 and Disease-Related Genes in Human Patients and in a Mouse Model of Alport Syndrome

Genetic Reprogramming with Stem Cells Regenerates Glomerular Epithelial Podocytes in Alport Syndrome

FAK contributes to proteinuria in hypercholesterolaemic rats and modulates podocyte F-actin re-organization via activating p38 in response to ox-LDL

Dual inhibition of the endothelin and angiotensin receptor ameliorates renal and inner ear pathologies in Alport mice

Integrin alpha1 beta1 promotes interstitial fibrosis in a mouse model of polycystic kidney disease

The immunosuppressive drug LF15-0195 acts also on glomerular lesions, by a change in cytoskeleton distribution in podocyte.

Autoantibodies Against Laminin-521 Are Pathogenic in Anti-Glomerular Basement Membrane Disease.

Increase in extracellular cross-linking by tissue transglutaminase and reduction in expression of MMP-9 contribute differentially to focal segmental glomerulosclerosis in rats

Novel Therapies for Alport Syndrome

MNK-driven eIF4E phosphorylation regulates the fibrogenic transformation of mesenchymal cells and chronic lung allograft dysfunction

Targeting Fibroblast-Endothelial Interactions in LAM Pathogenesis: 3D Spheroid and Spatial Transcriptomic Insights for Therapeutic Innovation

Plectin Protects Podocytes From Adriamycin-Induced Apoptosis And F-Actin Cytoskeletal Disruption Through The Integrin Alpha 6 Beta 4/Fak/P38 Mapk Pathway